Nevro Corp (NVRO)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Nevro Corp (NVRO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011515
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nevro Corp (Nevro) is a medical device company that offers therapeutic equipment. The company provides pain relief therapies for low back pain and other types of chronic pain. Its services include SCS therapy and clinical trials. Nevro’s SCS therapy is a low-frequency spinal cord stimulation therapy. The company uses implantable spinal cord stimulation system. It also develops high-frequency stimulation technology for chronic pain. Nevro offers HF10 therapy, a paresthesia free treatment to provide pain relief to patients. The company also conducts clinical and preclinical studies on back and leg pain. It serves the pain management needs of people. Nevro is headquartered in Redwood City, California, the US.

Nevro Corp (NVRO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nevro Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Nevro Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Nevro Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Nevro Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Nevro Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Nevro Corp, Medical Equipment, Deal Details 10
Venture Financing 10
Nevro Raises US$48 Million In Series C Financing 10
Nevro Secures US$58 Million In Financing 12
Equity Offering 14
Nevro Raises USD126 Million in Public Offering of Shares 14
Nevro Raises USD145 Million in IPO of Shares 16
Debt Offering 18
Nevro Completes Public Offering of 1.75% Notes Due 2021 for USD172.5 Million 18
Nevro Corp – Key Competitors 20
Nevro Corp – Key Employees 21
Nevro Corp – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 06, 2017: Nevro Reports Third Quarter 2017 Financial Results 23
Aug 07, 2017: Nevro Reports Second Quarter 2017 Financial Results 24
May 08, 2017: Nevro Reports First Quarter 2017 Financial Results 25
Feb 23, 2017: Nevro Reports Fourth Quarter and Full Year 2016 Financial Results and Provides 2017 Outlook 26
Nov 07, 2016: Nevro Reports Third Quarter 2016 Financial Results 27
Aug 08, 2016: Nevro Reports Second Quarter 2016 Financial Results 28
May 09, 2016: Nevro Reports First Quarter 2016 Financial Results 29
Feb 29, 2016: Nevro Reports Fourth Quarter and Full Year 2015 Financial Results 30
Jan 11, 2016: Nevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2015 Revenue 32
Corporate Communications 33
Feb 29, 2016: Nevro Announces Executive Succession 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Nevro Corp, Medical Equipment, Key Facts, 2016 2
Nevro Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Nevro Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Nevro Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Nevro Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Nevro Corp, Deals By Market, 2011 to YTD 2017 8
Nevro Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Nevro Raises US$48 Million In Series C Financing 10
Nevro Secures US$58 Million In Financing 12
Nevro Raises USD126 Million in Public Offering of Shares 14
Nevro Raises USD145 Million in IPO of Shares 16
Nevro Completes Public Offering of 1.75% Notes Due 2021 for USD172.5 Million 18
Nevro Corp, Key Competitors 20
Nevro Corp, Key Employees 21
Nevro Corp, Subsidiaries 22

★海外企業調査レポート[Nevro Corp (NVRO)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Miragen Therapeutics Inc (MGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), …
  • Coresa Sa:企業の戦略・SWOT・財務分析
    Coresa Sa - Strategy, SWOT and Corporate Finance Report Summary Coresa Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Probi AB (PROB):企業の財務・戦略的SWOT分析
    Probi AB (PROB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Sempra U.S. Gas & Power LLC-石油・ガス分野:企業M&A・提携分析
    Summary Sempra U.S. Gas & Power, LLC (Sempra US), a subsidiary of Sempra Energy, an energy solution provider, is a clean power solutions developer. It develops, designs, constructs and operates renewable energy and natural gas solutions, with a focus on zero and low emission fuels. The company owns …
  • Black Hills Corp (BKH):石油・ガス:M&Aディール及び事業提携情報
    Summary Black Hills Corp (BHC) is a vertically-integrated energy company which offers electricity and natural gas. The company produces, transmits, and distributes electricity; and sells natural gas on retail and wholesale basis. It generates electricity from natural gas, coal, diesel oil, and wind …
  • Ross Offshore AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Ross Offshore AS (Ross Offshore) is an oilfield service provider that provides project management and consultancy services. The company provides drilling and well, late life operation, subsurface, ross operations, HSEQ, consultancy services, and others. It offers late life operation services …
  • Simplex Infrastructures Ltd:企業の戦略・SWOT・財務分析
    Simplex Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report Summary Simplex Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Global Partners LP (GLP)-石油・ガス分野:企業M&A・提携分析
    Summary Global Partners LP (Global Partners) is a midstream logistics and marketing company. It carries out purchasing, selling and logistics of transporting domestic and Canadian crude oil and other products by rail across its virtual pipeline from the mid-continent region of the US and Canada to t …
  • SpareBank 1 Nord-Norge:企業の戦略・SWOT・財務分析
    SpareBank 1 Nord-Norge - Strategy, SWOT and Corporate Finance Report Summary SpareBank 1 Nord-Norge - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Oxford Performance Materials Inc-医療機器分野:企業M&A・提携分析
    Summary Oxford Performance Materials Inc (OPMI), a subsidiary of Arkema Inc is a chemical company that manufactures thermoplastic polymers. The company’s products include proprietary polyether ketone ketone formulations, additives, complex assemblies, biomedical raw materials, biomedical parts, robo …
  • Aerpio Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Aerpio Therapeutics Inc (Aerpio) is a biopharmaceutical company that develops novel monoclonal antibodies and small molecules. The company’s programs include a Tie-2 activator for diabetic macular edema and a hypoxia-inducible factor stabilizer for the treatment of inflammatory bowel disease …
  • NEC Corp (6701):企業の財務・戦略的SWOT分析
    NEC Corp (6701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Inzpire Limited:企業の戦略・SWOT・財務情報
    Inzpire Limited - Strategy, SWOT and Corporate Finance Report Summary Inzpire Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • A.H.A International Co., Ltd.:戦略・SWOT・企業財務分析
    A.H.A International Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary A.H.A International Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • IRLAB Therapeutics AB (IRLAB A):製薬・医療:M&Aディール及び事業提携情報
    Summary IRLAB Therapeutics AB (IRL) is a pharmaceutical company that discovers and develops drugs to treat central nervous system associated diseases. The company conducts flagship technology integrative screening process, a phenotypic screening and systems pharmacology process is used for developme …
  • Hibu Group Limited:戦略・SWOT・企業財務分析
    Hibu Group Limited - Strategy, SWOT and Corporate Finance Report Summary Hibu Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • AusNet Services Ltd (AST)-エネルギー分野:企業M&A・提携分析
    Summary AusNet Services Ltd (AusNet) is a diversified energy network business entity that transmits and distributes power. It owns and manages electricity transmission network in Victoria; and delivers electricity to various customer connection points in eastern Victoria including Melbourne’s outer …
  • Silence Therapeutics Plc (SLN):企業の財務・戦略的SWOT分析
    Summary Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure disease. The company develops pipeline products such as Atu027 and Atu111. Its Atu027 is developed for the treatment of pancreatic, head and neck cancer …
  • Envases Del Plata S.A.:企業の戦略・SWOT・財務分析
    Envases Del Plata S.A. - Strategy, SWOT and Corporate Finance Report Summary Envases Del Plata S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • New Britain Palm Oil Limited:企業の戦略・SWOT・財務情報
    New Britain Palm Oil Limited - Strategy, SWOT and Corporate Finance Report Summary New Britain Palm Oil Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆